Insider Sale: Director at $DRS Sells 6,438 Shares

Director David W Carey sold 6,438 shares of $DRS on 06-13-2025 for approximately $295,761, representing about 21.2% of their holdings; Carey now holds 23,882 shares. Over the past six months, $DRS insiders have executed 15 sales and zero purchases, including multiple sales from the CEO, CFO, and other executives. Institutional investors show mixed sentiment, with 133 increasing and 135 decreasing their positions in the last quarter, while analysts have issued a "Buy" rating with a median price target of $43.0.

Analysis

A notable insider transaction at Leonardo DRS, Inc. ($DRS) involved director David W. Carey selling 6,438 shares on June 13, 2025, for an estimated $295,761, equating to approximately $45.94 per share. This sale reduced Carey's holdings by a significant 21.2%, leaving him with 23,882 shares. This event is contextualized by a broader pattern of insider dispositions: over the past six months, $DRS insiders executed 15 sales and zero purchases. These sales include substantial volumes from top executives such as CEO William III Lynn (90,000 shares for ~$3.06 million), CFO Michael Dippold (26,618 shares for ~$870,408), and COO John Baylouny (four sales totaling 14,116 shares for ~$456,017). This consistent selling by key management contrasts with mixed institutional sentiment. In the last quarter, 133 institutional investors increased their $DRS positions while 135 decreased them. Significant divestitures include Silvercrest Asset Management Group LLC reducing its stake by 97.7% (1,223,529 shares) and Driehaus Capital Management LLC by 57.3% (1,100,547 shares). Conversely, Van Eck Associates Corp increased its holdings by 109.8% (808,798 shares) and T. Rowe Price Investment Management, Inc. by 16.0% (804,938 shares). On the analyst front, BTIG issued a "Buy" rating on May 5, 2025. The median price target from two analysts over the last six months is $43.0, with BTIG setting a $49.0 target and Truist Financial a $37.0 target. The provided sentiment score for $DRS is -0.5, indicating moderately negative sentiment, which aligns with the pronounced insider selling activity.

Key Decisions for Investors

• Investors should view the consistent and broad-based insider selling by multiple key executives, including the CEO and CFO, as a significant cautionary signal, potentially indicating management's perception of a full valuation or internal concerns not yet reflected in public disclosures.
• The mixed institutional ownership changes, with substantial new investments alongside large liquidations, warrant careful scrutiny of the underlying theses for these major portfolio adjustments, especially when contrasted with the unambiguous selling trend from insiders.
• Given that recent insider sales, such as Director Carey's at approximately $45.94 per share, are occurring at levels near or above the median analyst price target of $43.0, investors should critically assess the risk-reward profile, particularly if considering new positions or adding to existing ones as the stock approaches the higher end of analyst targets.